Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background Drug-induced liver injury (DILI) is an uncommon adverse drug reaction of increasing importance to the medical community, pharmaceutical industry, regulatory agencies and the general public. Objectives The Drug-Induced Liver Injury Network (DILIN) was established to advance understanding and research into DILI by initiating a prospective registry of patients with bona fide DILI for future studies of host clinical, genetic, environmental and immunological risk factors. The DILIN was also charged with developing standardized nomenclature, terminology and causality assessment instruments. Methods Five clinical sites, a data coordinating centre and senior scientists from the National Institute of Diabetes and Digestive and Kidney Diseases initiated the DILIN prospective study in September 2004. Eligible patients are required to meet minimal laboratory or histological criteria within 6 months of DILI onset and have other competing causes of liver injury excluded. Patients in the general community setting with pre-existing HIV, hepatitis B virus or hepatitis C virus infections and/or abnormal baseline liver biochemistries are eligible for enrollment. In addition, subjects with liver injury due to herbal products are eligible to participate. Control patients without DILI are also to be recruited in the future. Results All referred subjects undergo an extensive review of available laboratory, pathology and imaging studies. Subjects who meet pre-defined eligibility criteria at the 6-month study visit are followed for 2 years to better define the natural history of chronic DILI. Causality assessment is determined by a panel of three hepatologists who independently assign a causality score ranging from 1 (definite) to 5 (unlikely) as well as a severity score ranging from 1 (mild) to 5 (fatal). During the first 3 years, 367 subjects were enrolled into the DILIN prospective study. Conclusion DILIN is a multicentre research network charged with improving our understanding of the aetiologies, risk factors and outcomes of DILI in the US. The network is meeting the targeted enrollment of ten patients per month and is developing a repository of clinical data and biological samples for future studies of DILI pathogenesis and outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The US DILIN Expert Opinion process has not been externally validated and requires expert judgement.”
From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expert judgement is the approach used to assess causality in large prospective DILI registries such as the Spanish, the Latin American, the European, or the DILIN.”
From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Causality was assessed using the DILIN structured expert opinion causality approach.”
From Ashwagandha‐induced liver injury: A case series from Iceland and the US Drug‐Induced Liver Injury Network (2020) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Also, both registries have minimum enrollment criteria for liver enzyme and bilirubin elevation, so it is unclear how the RECAM may perform in less severe injuries.8, 10”
From A revised electronic version of RUCAM for the diagnosis of DILI (2022) · cites this paper as [8]
In the citing paper
“In response to these limitations, the Spanish, LATINDILI and Pro‐Euro DILI networks have combined the evaluation of suspected DILI cases by three experts and further assessment using causality scales, while the DILIN has developed a structured expert opinion process.”
From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [38]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
The PedsQL™* 4.0 as a Pediatric Population Health Measure: Feasibility, Reliability, and Validity
Varni, J. W., Burwinkle, T. M., Seid, M., & Skarr, D. (2003) · Ambulatory Pediatrics · doi:10.1367/1539-4409(2003)003<0329:tpaapp>2.0.co;2 · Cited by 2,324
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Self-citationPanahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Russo, J., Trujillo, C. A., Wingerson, D., Decker, K., Ries, R., Wetzler, H., & Roy-Byrne, P. (1998) · Medical Care · doi:10.1097/00005650-199805000-00015 · Cited by 1,308
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106 · cited 13×
“Symptoms include fatigue, nausea, vomiting, right upper quadrant pain, itching, skin rash, jaundice, weakness, anorexia or weight loss, which in the opinion of the investigator are due to DILI.”
InfluentialANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Research works printed but not linked: 6
- Varni, 2003, Ambul Pediatr, 3, 329, 10.1367/1539-4409(2003)003 · doi:10.1367/1539-4409(2003)003
- Nunez, 2005, Drug Saf, 38, 53
- Kleiner, 2007, Gastroenterology, 132, M1775
- Galan, 2005, J Clin Gastroenterol, 39, 64
- Mok, 2000, Clin Exp Rheumatol, 18, 363
- Rockey, 2007, Gastroenterology, 132, M1777
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Case definition and phenotype standardization in drug-induced liver injury
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., Hunt, C. M., Wilke, R. A., Avigan, M., Kaplowitz, N., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.58 · Cited by 944
Self-citationFeatures and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study
Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K. R., Watkins, P. B., Navarro, V., Barnhart, H., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.006 · Cited by 925
Self-citationChalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755
Self-citationRUCAM in Drug and Herb Induced Liver Injury: The Update
Danan, G., & Teschke, R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010014 · Cited by 729
Metadata
- Authors
- Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J.
- Affiliations
- University of Michigan (US)
- University of North Carolina at Chapel Hill (US)
- Indiana University Indianapolis (US)
- University of California, San Francisco (US)
- Duke Clinical Research Institute (US)
- Corresponding author
- Fontana, Robert J.
- Venue
- Drug Safety
- Published
- 2009
- Volume
- 32
- Issue
- 1
- Pages
- 55-68
- ISSN
- 0114-5916 (ISSN-L)
- PMC
- PMC3637941
- OpenAlex
- W2060470911
- Cited by
- 486
- References
- 51
- Citations by year
- 2026: 23 · 2025: 22 · 2024: 34 · 2023: 30 · 2022: 37 · 2021: 30 · 2020: 35 · 2019: 41 · 2018: 28 · 2017: 25 · 2016: 22 · 2015: 36 · 2014: 29 · 2013: 31 · 2012: 21
- FWCI
- 17.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5u01dk065211-22, 5u01dk065238-11, 5u01dk065193-05, 5u01dk065184-22)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK-065238, U01‐DK065193, U01 DK-065184, U24DK065176, U01 DK-065211, 1U01DK065238, 1U01DK065193, 1U01DK065211, 1U01DK065184, U01DK065201, U01DK065176)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- drug-induced liver injury, Drug-Induced Liver Injury Network, causality assessment, risk factors, adverse drug reactions, standardized terminology, hepatotoxicity
- MeSH terms
- Follow-Up Studies, Humans, Terminology as Topic, Prospective Studies, Registries, Research Design, Risk Factors, Severity of Illness Index, United States, National Institute of Diabetes and Digestive and Kidney Diseases (U.S.), Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct. https://app.cochat.ai/papers/10.2165/00002018-200932010-00005
- The paper
- Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009). Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct. Drug Safety. https://doi.org/10.2165/00002018-200932010-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.